Erratum to: Erenumab for the Prevention of Migraine, Including the Rationale, Findings and Clinical Implications of the LIBERTY Study

Migraine is a neurologic disease characterized by recurrent attacks of head pain and symptoms such as nausea, photophobia and phonophobia, which last hours to days.1 Attacks themselves can be disabling, and due to the often unpredictable and unavoidable nature of the attacks, the disease itself accounts for substantial disability.2 In fact, migraine affects 12% of the global […]

A university lecturer first experienced headaches during the summer of 1989, when he was aged 26 years. The headache periods initially lasted about 1 day and because the pain was in the trigeminal area both an optometrist and a dentist were consulted. The headaches gradually increased in length, severity and frequency over the ensuing 10 years, typically lasting […]

Treatment guidelines recommend preventive therapy for migraine, based primarily on the frequency of migraine attacks.1 Migraine-related burden of disease increases with the number of headache days; however, even fewer than 4 headache days per month can result in severe disability in addition to impairment during individual episodes.2,3 The needs of patients with migraine go beyond simply reducing […]